---
title: "Aspen Neuroscience falls 6% to 52-week low"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304294438.md"
description: "Aspen Neuroscience fell 6.35% to US$11.51."
datetime: "2026-11-04T14:32:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304294438.md)
  - [en](https://longbridge.com/en/news/304294438.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304294438.md)
generator: "portal-rs"
---

# Aspen Neuroscience falls 6% to 52-week low

Aspen Neuroscience (ASPE.US) fell more than **6%** during regular trading to **$11.51**, hitting a 52-week low.

The Nasdaq Composite is down 3.28% over the past five sessions.

The company's amended charter took effect on Nov. 2, 2026, coinciding with the closing of its initial public offering. Aspen Neuroscience issued 9.375 million shares of common stock at $15 per share, raising gross proceeds of approximately $140.6 million before underwriting discounts and expenses.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [ASPE.US](https://longbridge.com/en/quote/ASPE.US.md)

## Related News & Research

- [ARCH Venture Partners X Discloses 12.9% Stake in Aspen Neuroscience](https://longbridge.com/en/news/304929595.md)
- [OrbiMed Advisors Discloses Investment at Aspen Neuroscience, Inc. with 12.3% Stake](https://longbridge.com/en/news/304700413.md)
- [Aspen Neuroscience's Amended Bylaws Take Effect at IPO Closing](https://longbridge.com/en/news/304014788.md)
- [OrbiMed Advisors reports acquisition of $15 million in Aspen Neuroscience common shares](https://longbridge.com/en/news/304354913.md)
- [ARCH Venture Fund XIV Reports Acquisition of $18 Million in Aspen Neuroscience Common Shares](https://longbridge.com/en/news/304042044.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**